Core Viewpoint - A class action lawsuit has been filed against Perrigo Company plc for allegedly misleading investors regarding its financial health and operations, particularly related to its infant formula business acquired from Nestlé [5]. Group 1: Lawsuit Details - The class action lawsuit pertains to securities purchased between February 27, 2023, and November 4, 2025, and aims to address claims of materially false and misleading statements made by the defendants [1][5]. - Key allegations include significant underinvestment in the infant formula business, the need for substantial capital expenditures beyond stated estimates, and manufacturing deficiencies that led to overstated financial results [5]. Group 2: Investor Actions - Investors who purchased Perrigo securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested investors can join the class action by submitting a form or contacting the law firm directly, with a deadline to serve as lead plaintiff set for January 16, 2026 [3][6]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm emphasizes the importance of selecting qualified legal counsel with proven success in similar cases to represent investors effectively [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Molina Healthcare, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Molina Healthcare securities is from February 5, 2025, to July 23, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 2, 2025 [2]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions [3]. - Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company [3]. - The firm has consistently ranked highly in securities class action settlements, recovering hundreds of millions for investors [3]. Group 3: Case Allegations - The lawsuit alleges that Molina Healthcare failed to disclose several material adverse facts, including issues with medical cost trend assumptions and the impact on financial guidance for fiscal year 2025 [4]. - It is claimed that Molina's growth was dependent on a lack of utilization of various health services, which was not disclosed to investors [4]. - The lawsuit asserts that the positive statements made by Molina's management were materially misleading and lacked a reasonable basis [4].

Core Viewpoint - Marex Group plc is facing a potential class action lawsuit due to allegations of securities law violations, including misleading financial statements and undisclosed financial practices [5][6][2]. Group 1: Legal Action and Investigation - Faruqi & Faruqi, LLP is investigating claims against Marex Group and has set a deadline of December 8, 2025, for investors to seek the role of lead plaintiff in the class action lawsuit [2]. - Investors who purchased Marex securities between May 16, 2024, and August 5, 2025, are encouraged to contact the law firm to discuss their legal rights [1][2]. Group 2: Allegations Against Marex - The complaint alleges that Marex and its executives made false or misleading statements and failed to disclose critical financial information, including the sale of over-the-counter financial instruments to itself and inconsistencies in financial statements [5]. - A report by NINGI Research accused Marex of a multi-year accounting scheme involving off-balance-sheet entities and fictitious transactions, including a fabricated receivable of $17 million and nearly $1 billion in concealed derivatives exposure [6]. Group 3: Market Reaction - Following the release of the NINGI Research report, Marex's stock price dropped by 6.2%, closing at $35.31 with significant trading volume [8].

Core Viewpoint - Molina Healthcare, Inc. is facing a potential class action lawsuit due to allegations of misleading statements regarding its financial health and medical cost trends, with a deadline for investors to seek lead plaintiff status by December 2, 2025 [2][5]. Summary by Sections Legal Action - Faruqi & Faruqi, LLP is investigating claims against Molina Healthcare and encourages affected investors to contact them for legal options [1][2]. - The firm has a history of recovering significant amounts for investors since its establishment in 1995 [4]. Allegations Against Molina - The complaint alleges that Molina and its executives violated federal securities laws by making false or misleading statements and failing to disclose critical information regarding: 1. Medical cost trend assumptions [5]. 2. Dislocation between premium rates and medical costs [5]. 3. Dependency on low utilization of various health services for near-term growth [5]. 4. Likelihood of substantial cuts to financial guidance for fiscal year 2025 [5]. 5. Misleading positive statements about the company's business and prospects [5]. Financial Performance and Stock Impact - On July 7, 2025, Molina announced second-quarter results, revealing adjusted earnings of approximately $5.50 per share, which was below expectations due to medical cost pressures [6][8]. - The company cut its full-year adjusted earnings guidance by 10.2%, from at least $24.50 per share to a range of $21.50 to $22.50 per share [8]. - Following this announcement, Molina's stock price fell by $6.97, or 2.9%, closing at $232.61 per share on July 7, 2025 [8]. - On July 23, 2025, Molina further reduced its full-year earnings guidance, reporting a GAAP net income of $4.75 per diluted share for the second quarter, an 8% decrease year-over-year [9]. - The new guidance indicated a 13.6% cut to earnings per share, with full-year GAAP net income guidance reduced by 27% to $912 million [9]. - This led to a significant stock price drop of $32.03, or 16.84%, closing at $158.22 per share on July 24, 2025 [9].

Core Viewpoint - Rosen Law Firm is reminding purchasers of WPP plc American Depositary Shares (ADS) of the upcoming lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company during a specified class period [1][5]. Group 1: Class Action Details - The class period for the WPP ADSs is from February 27, 2025, to July 8, 2025, and the lead plaintiff deadline is December 8, 2025 [1]. - Investors who purchased WPP ADSs during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in this area [4]. - The firm has achieved significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in securities class action settlements [4]. Group 3: Allegations Against WPP - The complaint alleges that WPP provided overly positive statements while concealing material adverse facts about its media arm's ability to handle macroeconomic challenges, leading to a loss of market share [5].

Core Points - Rosen Law Firm is encouraging investors of Marex Group plc who incurred losses exceeding $100,000 during the Class Period from May 16, 2024, to August 5, 2025, to secure legal counsel before the December 8, 2025, deadline for lead plaintiff applications [1][2]. Group 1: Legal Action Details - Investors who purchased Marex securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm directly for more information [3][6]. - The lawsuit alleges that Marex made materially false and misleading statements, including selling over-the-counter financial instruments to itself and inconsistencies in financial statements, which led to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - A securities class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. for allegedly misleading investors regarding the company's financial performance and property valuations during the specified class period [1][2]. Group 1: Allegations and Financial Performance - The lawsuit claims that the defendants provided overly optimistic statements about the company's expected revenue and funds from operations (FFO) growth for fiscal year 2025, particularly regarding its real estate operations [2]. - On October 27, 2025, Alexandria reported disappointing financial results for Q3 2025, which included a significant real estate impairment charge of $323.9 million, with $206 million related to its Long Island City property [3]. - Following the announcement of these results, Alexandria's stock price dropped approximately 19%, falling from $77.87 per share to $62.94 per share [3]. Group 2: Legal Proceedings - Investors who acquired shares of Alexandria during the class period are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline on January 26, 2026 [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Alexandria Real Estate Equities, Inc. due to allegations of false and misleading statements regarding the company's Long Island City property and its financial performance [4][6]. Group 1: Legal Investigation - The firm is encouraging investors who suffered losses in Alexandria between January 27, 2025, and October 27, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Alexandria, with a deadline of January 26, 2026, for investors to seek the role of lead plaintiff [4][8]. - The complaint alleges that Alexandria and its executives violated federal securities laws by making false statements and failing to disclose adverse facts about the company's property [6]. Group 2: Financial Performance - Alexandria reported third quarter earnings for 2025 that fell short of analyst expectations, with a 5% decline in revenue and a 7% decline in adjusted funds from operation [7]. - The average occupancy rate for Alexandria declined from 94.8% in the prior year to 91.4% [7]. - Following the release of these financial results, Alexandria's stock price fell over 19% on October 28, 2025 [7].

Core Viewpoint - A class action lawsuit has been filed against StubHub Holdings, Inc. regarding its September 2025 IPO, alleging that the Registration Statement was materially false and misleading, impacting investors negatively [1][5]. Company Details - StubHub Holdings, Inc. is facing legal action due to claims that it misrepresented its financial health, particularly regarding changes in payment timing to vendors and its free cash flow [5]. - The lawsuit asserts that these misrepresentations led to misleading statements about StubHub's business operations and prospects, resulting in investor damages when the true information became public [5]. Legal Process - Investors who purchased StubHub common stock may be eligible for compensation without incurring out-of-pocket costs through a contingency fee arrangement [2]. - To participate in the class action, investors must act by January 23, 2026, to serve as lead plaintiff, which involves directing the litigation on behalf of other class members [3][5].

Core Viewpoint - A federal securities class action has been filed against CarMax, Inc. for allegedly overstating its growth prospects during a specific period, leading to significant investor losses following disappointing financial results [3][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased CarMax securities from June 20, 2025, to September 24, 2025, claiming that the company misrepresented its growth potential [3]. - CarMax's financial results for the second quarter of fiscal year 2026 revealed a 5.4% decrease in retail unit sales and a 6.3% decrease in comparable store unit sales, alongside a decline in net earnings per diluted share from $0.85 to $0.64 year-over-year [4]. Group 2: Market Reaction - Following the release of the disappointing earnings report on September 25, 2025, CarMax's share price fell by $11.50, or approximately 20.07%, closing at $45.60 [4].